HOT AIR BALLOON FLIGHT

In a highly unusual move, federal regulators pressed Pfizer and BioNTech to submit a request for emergency authorization, people familiar with the situation said, even though two doses failed to produce the hoped-for immune response among children aged two to four in a clinical trial.